Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 03 Jul 2024 for Tempest Therapeutics, Inc., €9,258.
Filing timeline
BuySaleSamuel Whiting
Insider track record
Disclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-28.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Samuel Whiting: trading record in brief
Samuel Whiting is a declared insider of Tempest Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). Between 25 June 2021 and 2 July 2024, the trades on record add up to 3 filings.
Purchases make up the whole of the open-market record (2 purchases, €16k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant. So far in 2024, the count stands at 1 purchase and no sales.
On 3 July 2024 came the latest disclosure, an open-market purchase for €9,258 in Tempest Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Samuel Whiting
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
4,672 shares@ US$2.1339.1% of flowCommon StockSEC:0001415889-24-019279:0
Canonical exit: 30 Sept 2024 (T+90)
1,700 shares@ US$4.804843.8% of flowCommon StockSEC:0001209191-22-002753:0
Canonical exit: 6 Apr 2022 (T+90)
201 sharesCommon StockSEC:0001140361-21-022931:0
3 of 3 declarations
